Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone (Kd), 2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone (Kd)
### Instruction:
Identify the study with the following condition. 
### Input:
Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone (Kd), 2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone (Kd) 
### Output:
Popular Name is ARROW, Study ID is NCT02412878